The Clinical Laboratory Price Transparency Act of 2023 requires Medicare-participating laboratories to publicly disclose prices for specific clinical tests, including discounted cash prices and negotiated rates with health insurance plans. Starting January 1, 2025, labs must post this information on a standardized website (with annual updates) in a format established by the Department of Health and Human Services by 2028. Non-compliant labs face civil penalties of up to $300 per day after a 90-day correction period. This applies only to laboratories providing tests listed as "shoppable services" under Medicare (e.g., common blood or urine tests, excluding advanced diagnostic tests).
HR 4794, the Dietary Supplements Access Act, allows health savings accounts (HSAs), flexible spending accounts (FSAs), and health reimbursement arrangements (HRAs) to cover dietary supplements as qualified medical expenses. The bill amends the Internal Revenue Code to treat payments for dietary supplements - defined under federal law (21 U.S.C. 321(ff)) - as medical care, directly affecting individuals using these accounts to pay for supplements like vitamins or minerals. Key provisions require HSAs, FSAs, and HRAs to reimburse supplement costs under the same rules as other medical expenses. The change applies to taxable years beginning after the bill’s enactment.
HR 4673, the Ending Normal Trade Relations with China Act of 2023, would end the U.S. policy granting China lower tariffs on its exports. If enacted, it would require all Chinese-made goods to pay standard U.S. tariffs (the rates in column 2 of the Harmonized Tariff Schedule) starting two years after the law's passage, instead of the reduced "normal trade relations" rates. The bill also prevents future extension of this preferential status and allows the President to further increase tariffs on Chinese products. This change would directly affect Chinese exporters and U.S. importers of Chinese goods by raising their costs.
HR 4307, the Medical Supply Chain Resiliency Act, establishes a framework for the U.S. to negotiate agreements with trusted foreign partners to secure reliable supplies of critical medical goods like drugs and devices. It directs the President to create "trusted trade partner agreements" with countries that maintain open trade during health emergencies, protect intellectual property, and reduce unnecessary trade barriers. These agreements would eliminate duties or restrictions on medical goods, diversify supplier networks, and harmonize regulatory standards to prevent shortages like those seen during the pandemic. The bill directly affects U.S. manufacturers, healthcare providers, and importers by aiming to reduce over-reliance on a few nations for essential medical products.
HR 4073, the Duty Drawback Clarification Act, clarifies U.S. tariff classifications for imported whiskies by creating specific subheadings in the Harmonized Tariff Schedule. It replaces a single tariff line with eight new subheadings that categorize whiskies by type (Irish/Scotch, Bourbon, Rye, or "Other") and container size (under or over 4 liters), each with a uniform duty rate of $2.04 per liter. This change directly affects whiskey importers and manufacturers who must now classify products using these new codes when entering goods into U.S. commerce. The bill streamlines duty calculation and drawback claims (refunds of duties on imported goods later exported) by standardizing the tariff structure for whiskey categories.
The Leveling the Playing Field 2.0 Act (HR 3882) updates U.S. trade law to better address international trade practices that disadvantage American businesses. It establishes special rules for handling multiple investigations of the same merchandise (called "successive investigations"), requiring the Commerce Department to consider previous injury determinations when making new findings. The bill also creates mechanisms to address market distortions from foreign government subsidies, including currency undervaluation, and strengthens procedures to prevent duty evasion through certification requirements for importers. These changes primarily affect foreign exporters of goods subject to U.S. antidumping and countervailing duty investigations, as well as U.S. importers of those goods.
HR 3739, the FAIR TARIFF Act of 2023, requires U.S. Customs to refund overpaid duties for specific imports from European Union countries during two defined periods: October 18-December 17, 2019, and January 12-February 10, 2022. It targets products classified under certain Harmonized Tariff Schedule codes (e.g., 9903.89.10-9903.89.49 for 2019, 9903.89.57-9903.89.59 for 2022) that were incorrectly taxed due to tariff misclassification. Importers must apply for refunds within one year of the law’s enactment, with refunds processed within 180 days of application. The bill also mandates a 60-day advance notice in the Federal Register before implementing new tariff increases under Section 301 of the Trade Act of 1974.
This bill simplifies regulations for rural health clinics (RHCs) by reducing administrative burdens. It allows RHCs to contract with physician assistants and nurse practitioners (instead of requiring direct employment), updates the definition of "rural" to exclude areas with 50,000+ residents, and removes outdated lab service requirements by requiring only "prompt access" to clinical labs. These changes directly affect RHCs, enabling them to more flexibly staff and operate while complying with state practice laws. The amendments take effect January 1, 2024, applying to services provided on or after that date.
This bill establishes a minimum payment floor for Medicare reimbursements to rural hospitals not located in frontier states. It sets a 0.85 minimum for the area wage index used in hospital inpatient payments (starting October 2023) and a similar floor for outpatient department payments (starting January 2024). This prevents Medicare payments from dropping below 85% of the standard wage index for eligible rural hospitals. The bill includes budget neutrality requirements to ensure overall Medicare payments don't increase, while exempting hospitals already receiving payments above the floor.
HR 3611, the Kazakhstan Permanent Normal Trade Relations Act of 2023, makes Kazakhstan's existing "normal trade relations" (NTR) status permanent by removing the need for annual U.S. presidential reviews under the Trade Act of 1974. This bill directly affects U.S. trade policy with Kazakhstan, ending the requirement for the President to annually determine whether Kazakhstan meets emigration freedom standards (which it has satisfied since 1997). The key provision allows the President to formally extend permanent NTR treatment to Kazakhstan's products, eliminating the current annual review process. Once enacted, Kazakhstan would automatically receive the same most-favored-nation tariff rates as other NTR countries, streamlining trade without further congressional action.
This bill removes geographic restrictions on Medicare telehealth services, allowing rural beneficiaries to receive care at home or remotely starting January 1, 2025. It specifically expands access for critical access hospitals and rural health clinics by standardizing payments for telehealth services and permitting audio-only visits for certain providers like doctors and clinics with established patient relationships. The bill also extends Medicare flexibilities for Federally Qualified Health Centers (FQHCs) and rural health clinics beyond 2024. These changes aim to improve healthcare access in underserved rural communities by removing prior barriers to telehealth.
This bill prohibits federal funding for gender transition procedures - including hormone therapy, puberty blockers, and surgeries like genital reassignment - across all federal programs and health plans. It exempts procedures for medical conditions (such as disorders of sex development) and treatment of complications arising from such procedures. The bill also blocks Affordable Care Act premium tax credits and cost-sharing reductions for health plans covering these services, though individuals may purchase separate non-federal-funded coverage. State and private insurers can still offer such coverage using their own funds, but federal subsidies cannot be applied to it.
